Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma


Por: Peñalver FJ, Delgado J, Loscertales J, Sastre JL, Peña A, Olave MT, Osorio S, de la Fuente A, Salar A, Grande C, Pérez Ceballos E, Debén G, Echeveste A, Casado F, de la Rubia J, Lahuerta JJ and Mateos MV

Publicada: 1 may 2016 Ahead of Print: 9 ago 2015
Resumen:
Bendamustine is an increasingly used hybrid alkylating agent that is active in lymphoid neoplasias via a novel mechanism of action. There are some pending questions about its use in clinical practice because of its developmental features. A consensus panel of several leading Spanish hematologists with broad experience in the clinical use of bendamustine has established recommendations for the management and treatment of hematological patients with bendamustine based on available clinical data and theexperience of the participants. These recommendations address the dose and treatment regimen fordifferent clinical indications, the management of toxicity, and support therapy. This article contains the conclusions of this consensus panel, which are intended to serve as guidelines for the use of bendamustine.

Filiaciones:
Peñalver FJ:
 Department of Hematology, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain

Delgado J:
 Department of Hematology, Hospital Clinic, Barcelona, Spain

Loscertales J:
 Department of Hematology, Hospital Universitario de La Princesa, Madrid, Spain

Sastre JL:
 Department of Hematology, Complexo Hospitalario de Ourense, Ourense, Spain

Peña A:
 Department of Hematology, Hospital Universitario San Carlos, Madrid, Spain

Olave MT:
 Department of Hematology, Hospital Universitario Lozano Blesa, Zaragoza, Spain

Osorio S:
 Department of Hematology, Hospital Universitario Gregorio Marañón, Madrid, Spain

de la Fuente A:
 Department of Hematology, MD Anderson Cancer Center, Madrid, Spain

Salar A:
 Department of Hematology, Hospital del Mar, Barcelona, Spain

Grande C:
 Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain

Pérez Ceballos E:
 Department of Hematology, Hospital Universitario Morales Messeguer, Murcia, Spain

Debén G:
 Department of Hematology, Complexo Hospitalario de La Coruña, La Coruña, Spain

Echeveste A:
 Department of Hematology, Hospital Universitario Donostia, San Sebastián, Spain

Casado F:
 Department of Hematology, Hospital Virgen de la Salud, Toledo, Spain

:
 Department of Hematology, Hospital Universitario Doctor Peset, Valencia, Spain

Lahuerta JJ:
 Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain

Mateos MV:
 Department of Hematology, IBSAL-Hospital Universitario de Salamanca, Salamanca, Spain
ISSN: 09024441





EUROPEAN JOURNAL OF HAEMATOLOGY
Editorial
WILEY-BLACKWELL, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Reino Unido
Tipo de documento: Article
Volumen: 96 Número: 5
Páginas: 532-540
WOS Id: 000374147300011
ID de PubMed: 26179864

MÉTRICAS